Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.30 |
| ▸ | HTR3B | O95264 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR3A | P46098 | 2/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053587 | 0.89 | POLB (0.37) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL25801003 | 0.89 | POLB (0.37) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL17274205 | 0.89 | POLB (0.37) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL21133587 | 0.89 | POLB (0.37) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL18053577 | 0.89 | POLB (0.30) | POLB | |
| SCHEMBL18053590 | 0.85 | POLB (0.34) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL18053581 | 0.85 | POLB (0.34) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL17274204 | 0.85 | HTR3E (0.36) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL25801001 | 0.85 | HTR3E (0.36) | POLBHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL17274206 | 0.83 | POLB (0.36) | POLBHTR3EHTR3BHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | GENENTECH, INC. (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218782-A1 | IMAGING METHODS USING DEUTERATED COMPOUNDS | SLC10A1, SLC9B2, RXFP1 | POLB 3748/4885HTR3E 1205/4885HTR3B 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.